Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Daunorubicin
  • Idarubicin
  • Leukemia, Myeloid

abstract

  • It is essential that the median length of follow-up be clearly stated in any clinical trial. When the results obtained with a particularly promising new drug or procedure are presented early in the course of study (within 1-2 years), the investigators should strongly consider a repeat evaluation after an additional 3-5 years of follow-up.

publication date

  • December 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9395031

Additional Document Info

start page

  • 2181

end page

  • 5

volume

  • 80

number

  • 11 SUPPL.